Losartan efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Losartan Efficacy in Hypertension and Related Conditions
Losartan is widely recognized as an effective antihypertensive medication. Clinical trials involving thousands of patients with mild to severe essential hypertension have shown that losartan, whether used alone or with low-dose hydrochlorothiazide (HCTZ), significantly lowers both systolic and diastolic blood pressure. Its efficacy is comparable to other common antihypertensive agents such as enalapril, felodipine, and atenolol, and it provides consistent blood pressure control over a 24-hour period 123. In Asian and African American populations, losartan also effectively reduces blood pressure, though the response in Black patients may be somewhat smaller. Combining losartan with HCTZ enhances its blood pressure-lowering effect, especially in patients who do not respond adequately to monotherapy 57.
In patients with post-dialysis euvolemic hypertension, losartan 50 mg significantly reduced blood pressure over 12 months, with fewer deaths reported compared to standard therapy . In children with immunoglobulin A (IgA) nephropathy, losartan reduced proteinuria by more than 50% in about 40% of patients over 24 weeks, without negatively affecting kidney function .
Losartan Safety and Tolerability
Losartan is generally well tolerated, with an adverse event profile similar to placebo. The most common side effect reported is dizziness, but its incidence is low (2.4% vs. 1.3% for placebo). Other side effects such as headache, upper respiratory tract infection, and fatigue occur at rates similar to placebo. The rate of withdrawal due to adverse events is actually lower with losartan than with placebo 16. Cough, a common side effect of ACE inhibitors, is less frequent with losartan .
Losartan is considered safe for patients with diabetes, renal impairment, or heart failure, and can be used as a first-line or alternative therapy, especially for those who experience side effects with other antihypertensive agents . In studies involving children and patients with kidney disease, losartan did not cause significant changes in kidney function, supporting its safety in these populations .
Losartan in Special Populations and Conditions
In African American patients, losartan monotherapy is effective but combining it with HCTZ provides greater blood pressure reductions. Both regimens are as well tolerated as placebo . In Asian populations, losartan is effective and offers additional benefits such as renal protection in diabetic patients and those with heart failure, though more studies are needed to confirm these findings in diverse ethnic groups .
For patients with hypertrophic cardiomyopathy, losartan did not significantly reduce left ventricular mass compared to placebo, but it was safe and well tolerated, even in those with left ventricular outflow obstruction .
Topical Losartan for Corneal Fibrosis
Animal and early human studies suggest that topical losartan is effective and safe for preventing or treating corneal scarring fibrosis. However, higher dosages may cause toxicity, so careful dosing is recommended .
Conclusion
Losartan is a well-established, effective, and safe antihypertensive agent for a wide range of patients, including those with comorbidities such as diabetes, kidney disease, and heart failure. It is generally well tolerated, with a side effect profile similar to placebo, and can be safely combined with other antihypertensive agents for enhanced efficacy. Losartan also shows promise in other conditions, such as proteinuric kidney disease and corneal fibrosis, further supporting its versatility and safety in clinical practice 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic